ArticleJournal of neurology, neurosurgery, and psychiatry2023
Association of serum neurofilament light with microglial activation in multiple sclerosis.
Article in Journal of neurology, neurosurgery, and psychiatry, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 2 syntheses or guidelines pooled it, 21 citations in OpenAlex.
- Evaluating the Clinical Utility of TSPO-PET in MS and the Influence of Methodological Heterogeneity: A Systematic Review and Meta-Analysis.Neurology(R) neuroimmunology & neuroinflammation · 2026Pooled it
- Serum neurofilament light chain and multiple sclerosis prognosis: a systematic review and meta-analysis.Frontiers in immunology · 2026Pooled it
- Impact of Oral Cladribine on TSPO-PET-Measurable Immune Cell Activation in Multiple Sclerosis.Neurology and therapy · 2026Article
- Baseline Neuroinflammation Stratifies TSPO-PET Response to Disease-Modifying Therapy in Multiple Sclerosis.Annals of clinical and translational neurology · 2026Article
- Plasma neurofilament light chain: A novel biomarker of neuroaxonal injury associated with depressive symptoms in epilepsy.Epilepsia · 2026Article
- Association between post-COVID-19 neuropsychiatric symptoms and persistent glial activation in the limbic system: a TSPO PET study.Journal of neurology · 2026Article
- Plasma neurofilament light reflects more severe manifestation of Alzheimer's disease in men.Molecular psychiatry · 2025Article
- Plasma CHI3L1 associates with brain volume loss and glial activation in multiple sclerosis.Journal of neurology, neurosurgery, and psychiatry · 2025Article
- Primary Progressive Multiple Sclerosis: New Therapeutic Approaches.Neuropsychopharmacology reports · 2025Review
- Role of Ocrelizumab in modulating gene and microRNA expression in multiple sclerosis.Non-coding RNA research · 2025Article
- Harnessing human iPSC-microglia for CNS-wide delivery of disease-modifying proteins.Cell stem cell · 2025Article
- Transcriptomic profiling identifies ferroptosis and NF-κB signaling involved in α-dimorphecolic acid regulation of microglial inflammation.Journal of translational medicine · 2025Article
- Increased TSPO alleviates neuropathic pain by preventing pyroptosis via the AMPK-PGC-1α pathway.The journal of headache and pain · 2025Article
- The Dual Role of Microglia in Multiple Sclerosis and its Implications for Diagnostics and Repair.Current neuropharmacology · 2025Review
- The role of microglia in multiple sclerosis: implications for treatment with Bruton's tyrosine kinase inhibitors.Frontiers in immunology · 2025Review
- Serum glial fibrillary acid protein associates with TSPO-expressing lesions in multiple sclerosis brain.Therapeutic advances in neurological disorders · 2025Article
- Predictors of risk of secondary progression in multiple sclerosis.Therapeutic advances in neurological disorders · 2025Article
- Serum neurofilament light and glial fibrillary acidic protein levels are not associated with wearing-off symptoms in natalizumab-treated multiple sclerosis patients.Multiple sclerosis (Houndmills, Basingstoke, England) · 2024Article
- Sex-driven variability in TSPO-expressing microglia in MS patients and healthy individuals.Frontiers in neurology · 2024Article
- Chronic active lesions in multiple sclerosis: classification, terminology, and clinical significance.Therapeutic advances in neurological disorders · 2024Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 3 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundTranslocator protein (TSPO)-PET and neurofilament light (NfL) both report on brain pathology, but their potential association has not yet been studied in multiple sclerosis (MS) in vivo. We aimed to evaluate the association between serum NfL (sNfL) and TSPO-PET-measurable microglial activation in the brain of patients with MS.
methodsMicroglial activation was detected using PET and the TSPO-binding radioligand [
results44 patients with MS (40 relapsing-remitting and 4 secondary progressive) and 24 age-matched and sex-matched healthy controls were included. In the patient group with elevated brain [
conclusionsOur demonstration of an association between microglial activation as measured by increased TSPO-PET signal, and elevated sNfL emphasises the significance of smouldering inflammation for progression-promoting pathology in MS and highlights the role of rim-active lesions in promoting neuroaxonal damage.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.